Latest news with #Danish
7NEWS
an hour ago
- 7NEWS
Workers from Laos bar where Aussie teenagers Holly Bowles and Bianca Jones died of methanol poisoning flee country to new jobs
Two workers employed at the Laos bar where two Australian travellers died of methanol poisoning have fled the country. They had been working at the Nana Backpackers Hostel when the 19-year-old Melbourne women, Holly Bowles and Bianca Jones, became two of six international victims that died after drinking the tainted alcohol in the establishment. The Herald Sun revealed on Friday that the two men, employed as a bartender and a hostel manager at the time of the incident in November last year, have found new jobs in Vietnam. After they fled the Laos tourist town of Vang Vieng, the outlet reports that the former hostel manager, known as Pikachu, was employed at a new hostel in his home country of Vietnam, and that the former bartender was now employed at a hotel there. The two men were among those detained after the incident. Hotel staff and management were among at least eight people taken into police custody. The Laotian government vowed to 'bring the perpetrators to justice in accordance with the law'. But no charges have been filed, and officials in Laos have released almost no details in the mass poisoning case since November. Alongside the Melbourne teens, an American man, two Danish women and a British woman died of methanol poisoning at the hostel. Jones and Bowles had joined other guests for free shots of alcohol offered by the hostel before going out for the night, but after becoming ill, did not leave their room for 24 hours and failed to check out as scheduled. They were taken to a hospital in Laos before being transferred to Thailand, where they were treated in two separate Bangkok hospitals after their parents raced to be by their bedsides. Jones' father Mark, upon learning of the whereabouts of the bartender and hostel manager, told the Herald Sun: 'We want the Australian Government to apply as much pressure as they can to bring justice to all those involved in the methanol poisoning of our girls.' Methanol is a form of alcohol commonly used in cleaning and industrial products, but it is toxic for humans and drinking as little as 30ml can be lethal. Outbreaks of methanol poisoning occur when the chemical is added to alcoholic drinks, either inadvertently through traditional brewing methods or deliberately — usually in the pursuit of profit. Thousands of people suffer from methanol poisoning every year, with most cases reported in Asia from people drinking bootlegged liquor or homemade alcohol. Many Southeast Asian nations have low safety standards, patchy regulatory enforcement and high levels of police corruption. Stream free on
Economic Times
5 hours ago
- Business
- Economic Times
Big fat legal war bursts out ahead of Novo Nordisk's Wegovy launch
Live Events Next Hearing on Aug 19 (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel A high-stakes legal battle has erupted ahead of the anticipated launch of Novo Nordisk 's blockbuster weightloss drug Wegovy (semaglutide) in India. The Delhi High Court has restrained Dr Reddy's Laboratories (DRL) and OneSource Specialty Pharma from selling semaglutide in the domestic market, following a patent infringement plea by the Danish the court, in an interim order Thursday, has not barred the Indian companies from manufacturing and exporting the drug. 'The defendants have alicence to manufacture the impugned drug, which was granted in December 2024, and have begun manufacturing the drug in April 2025,' noted the order uploaded late added that 'the defendants reserve their right to export the impugned drug in countries where the plaintiff has not been granted a patent yet'.Novo Nordisk on May 26 filed a patent infringement suit against Hyderabad-based Dr Reddy's and contract drugmaker OneSource before the Delhi HC. This was a countermove after Dr Reddy's on May 14 moved the HC seeking revocation of Novo Nordisk's patent for semaglutide—the active ingredient in Wegovy and Ozempic, the Danish firm's popular obesity and diabetes drugs. Novo Nordisk has alleged that Dr Reddy's and OneSource are importing large quantities of semaglutide active pharmaceutical ingredient (API) into India, and using it to manufacture and export violated Novo's patent rights, it claimed.A single-judge bench of the Delhi HC has posted the matter for further hearing on August 19, along with Dr Reddy's patent challenge, a senior lawyer told experts expect Novo Nordisk to appeal the interim order before a division bench as the single bench has not restrained the Indian companies from exporting semaglutide. 'Novo Nordisk is taking active steps to protect its inventions in India,' a company spokesperson said. The company said its semaglutide patents are protected in India and it expects continued support and protection of innovation in the country. 'However, we would not like to comment on a sub-judice matter,' the spokesperson a statement to ET, a Dr Reddy's spokesperson said, 'The matter is currently sub judice. We are unable to comment on it at this time.'A spokesperson for OneSource, too, declined comment citing the same a 650-page petition, Novo Nordisk said it became aware of the infringements of its valid patent number IN 262697 in India in October and November 2024.
India Gazette
5 hours ago
- Politics
- India Gazette
MP Amar Singh raises alarm over cross-border terror, drug threats at Denmark diaspora meet
Copenhagen [Denmark], May 31 (ANI): Congress MP Amar Singh, part of the all-party delegation, addressed the Indian diaspora in Copenhagen, raising concerns over Pakistan's involvement in cross-border terrorism and drug trafficking. He urged the Indian community to remain united in confronting such external threats. At the same event, India's Ambassador to Denmark, Manish Prabhat, responded to anti-India slogans raised by a small group outside the venue hosting the Indian parliamentary delegation. Hitting out at the protestors outside the venue, Ambassador Prabhat said, 'This community is unlike the community, a representation of which you saw outside on the street. And we know that how much amount they have been paid to put their duty here.' He further praised the Indian diaspora in Denmark, highlighting their positive contributions and cultural integration. Prabhat said, 'I would like to inform you that the Indian diaspora in Denmark is a thriving community. It has a strength of about 21,000 people now and the Danish society admires them. Because they are known for their hard work, their sincerity, their talent, their skills, their contribution to the Danish economy, their willingness to integrate, their respect for Danish culture and the fact that the Indian community is regarded as a vibrant community bringing the diverse cultures of India in all its colors and is known for promoting peace.' Also speaking at the gathering, Congress MP Dr Amar Singh voiced serious concerns over cross-border drug and weapon smuggling in across the Punjab border. 'In Punjab, especially after 1971, what happened was that opium was used to be sent from Pakistan. Punjab is the centre in North India for transporting drugs to Delhi and other parts of India. And I'm an eyewitness to those things. As a child, as a school student, then college student, and now for the last eight to ten years, again, as an eyewitness, that drugs and weapons are coming through drones,' he said. Singh further noted that several drones carrying narcotics and arms have been recovered from Punjab's border villages in recent years. Referring to past terror attacks in India, he said, 'When we know the reality that our neighbouring country, Pakistan, is doing this thing, how can we be quiet on this issue? And this issue has to be shared, and we all want to share with the international community that the issue of terrorism is now very serious. And in India, you will all remember Mumbai and then Pulwama, Uri, Pathankot and now Pahalgam. We all have to be united, oppose it. Terrorism is bad. Drugs are bad, weapons are bad, it damages the society.' Earlier, the Group 2 all-party delegation led by Bharatiya Janata Party (BJP) MP Ravi Shankar Prasad attended the luncheon interaction with former Danish parliamentarians in Copenhagen. The event, hosted by the Indian Ambassador, provided a platform for discussion and exchange of ideas. The delegation's engagement with former MPs, including Freddy Svane, former ambassador of Denmark to India, Manu Sareen, former MP and author Helle Degn, vice president of the Mandela Center, and Niels Ahlmann-Ohlsen, former MP and currently CEO of Strategic Alliance International ApS, aimed to foster stronger ties between India and Denmark. Apart from Ravi Shankar Prasad, other members of the Indian delegation included BJP MP Daggubati Purandeswari, Shiv Sena-UBT MP Priyanka Chaturvedi, Congress MPs Ghulam Ali Khatana and Amar Singh, and Ambassador Pankaj Saran. (ANI)
Time of India
5 hours ago
- Business
- Time of India
Big Fat Legal War Bursts Out aheadof Wegovy Launch
Live Events A high-stakes legal battle has erupted ahead of the anticipated launch of Novo Nordisk 's blockbuster weight-loss drug Wegovy (semaglutide) in India. The Delhi High Court has restrained Dr Reddy's Laboratories (DRL) and OneSource Specialty Pharma from selling semaglutide in the domestic market, following a patent infringement plea by the Danish the court, in an interim order Thursday, has not barred the Indian companies from manufacturing and exporting the drug. 'The defendants have a licence to manufacture the impugned drug, which was granted in December 2024, and have begun manufacturing the drug in April 2025,' noted the order uploaded late added that 'the defendants reserve their right to export the impugned drug in countries where the plaintiff has not been granted a patent yet'.Novo Nordisk on May 26 filed a patent infringement suit against Hyderabad-based Dr Reddy's and contract drugmaker OneSource before the Delhi HC. This was a countermove after Dr Reddy's on May 14 moved the HC seeking revocation of Novo Nordisk's patent for semaglutide— the active ingredient in Wegovy and Ozempic, the Danish firm's popular obesity and diabetes drugs. Novo Nordisk has alleged that Dr Reddy's and OneSource are importing large quantities of semaglutide active pharmaceutical ingredient (API) into India, and using it to manufacture and export violated Novo's patent rights, it claimed.A single-judge bench of the Delhi HC has posted the matter for further hearing on August 19, along with Dr Reddy's patent challenge, a senior lawyer told experts expect Novo Nordisk to appeal the interim order before a division bench as the single bench has not restrained the Indian companies from exporting semaglutide.'Novo Nordisk is taking active steps to protect its inventions in India,' a company spokesperson said. The company said its semaglutide patents are protected in India and it expects continued support and protection of innovation in the country. 'However, we would not like to comment on a sub-judice matter,' the spokesperson a statement to ET, a Dr Reddy's spokesperson said, 'The matter is currently sub judice. We are unable to comment on it at this time.'A spokesperson for OneSource, too, declined comment citing the same a 650-page petition, Novo Nordisk said it became aware of the infringements of its valid patent number IN 262697 in India in October and November 2024.
Time of India
5 hours ago
- Business
- Time of India
Big fat legal war bursts out ahead of Novo Nordisk's Wegovy launch
Novo Nordisk has filed a lawsuit in Delhi High Court. The suit aims to stop Dr Reddy's Laboratories and OneSource from selling semaglutide in India. Semaglutide is the active ingredient in Wegovy. The court has restrained the Indian companies from selling the drug domestically. However, they can still manufacture and export it. The next hearing is scheduled for August 19. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Next Hearing on Aug 19 A high-stakes legal battle has erupted ahead of the anticipated launch of Novo Nordisk 's blockbuster weightloss drug Wegovy semaglutide ) in India. The Delhi High Court has restrained Dr Reddy's Laboratories (DRL) and OneSource Specialty Pharma from selling semaglutide in the domestic market, following a patent infringement plea by the Danish the court, in an interim order Thursday, has not barred the Indian companies from manufacturing and exporting the drug. 'The defendants have alicence to manufacture the impugned drug, which was granted in December 2024, and have begun manufacturing the drug in April 2025,' noted the order uploaded late added that 'the defendants reserve their right to export the impugned drug in countries where the plaintiff has not been granted a patent yet'.Novo Nordisk on May 26 filed a patent infringement suit against Hyderabad-based Dr Reddy's and contract drugmaker OneSource before the Delhi HC. This was a countermove after Dr Reddy's on May 14 moved the HC seeking revocation of Novo Nordisk's patent for semaglutide—the active ingredient in Wegovy and Ozempic, the Danish firm's popular obesity and diabetes drugs. Novo Nordisk has alleged that Dr Reddy's and OneSource are importing large quantities of semaglutide active pharmaceutical ingredient (API) into India, and using it to manufacture and export violated Novo's patent rights, it claimed.A single-judge bench of the Delhi HC has posted the matter for further hearing on August 19, along with Dr Reddy's patent challenge, a senior lawyer told experts expect Novo Nordisk to appeal the interim order before a division bench as the single bench has not restrained the Indian companies from exporting semaglutide. 'Novo Nordisk is taking active steps to protect its inventions in India,' a company spokesperson said. The company said its semaglutide patents are protected in India and it expects continued support and protection of innovation in the country. 'However, we would not like to comment on a sub-judice matter,' the spokesperson a statement to ET, a Dr Reddy's spokesperson said, 'The matter is currently sub judice. We are unable to comment on it at this time.'A spokesperson for OneSource, too, declined comment citing the same a 650-page petition, Novo Nordisk said it became aware of the infringements of its valid patent number IN 262697 in India in October and November 2024.
